tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis
PremiumCompany AnnouncementsCardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis
18d ago
Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential
Premium
Ratings
Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential
2M ago
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Premium
TipRanks Newswire
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
2M ago
Cardiol Therapeutics Secures U.S. Patent for Heart Drugs
PremiumCompany AnnouncementsCardiol Therapeutics Secures U.S. Patent for Heart Drugs
3M ago
Cardiol Therapeutics to Present Promising ARCHER Trial Results at ESC Meeting
Premium
Company Announcements
Cardiol Therapeutics to Present Promising ARCHER Trial Results at ESC Meeting
3M ago
Cardiol Therapeutics Raises $16 Million Through Recent Securities Distribution
Premium
Company Announcements
Cardiol Therapeutics Raises $16 Million Through Recent Securities Distribution
3M ago
Cardiol Therapeutics trading halted, news pending
PremiumThe FlyCardiol Therapeutics trading halted, news pending
4M ago
Cardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx
Premium
Ratings
Cardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx
6M ago
Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses
Premium
Company Announcements
Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100